A new study reveals how C210, a curcumin derivative, selectively reactivates Epstein–Barr virus to kill cancer cells without infectious risks, paving the way for safer, targeted cancer therapies.

Francesca has an MSci in Biochemistry from the University of Birmingham.View full profile Francesca has an MSci in Biochemistry from the University of Birmingham. Epstein-Barr Virus (EBV) is very ...

New research in the latest issue of the Journal of Virology has identified a role for Epstein–Barr virus (EBV) latent membrane protein 1 (LMP1) in the production of virus during the viral lytic cycle.

Researchers at the Wistar Institute and their collaborators say they have discovered a potential target for gastric cancers associated with Epstein-Barr Virus. The study “Decitabine disrupts EBV ...

Phase I clinical and pharmacokinetic (PK) trial of the kinesin spindle protein (KSP) inhibitor MK-0731 in cancer patients No significant financial relationships to disclose. This is an ASCO Meeting ...